ZBD(SH:603567) Shang Hai Zheng Quan Bao·2025-12-02 19:19Core Viewpoint - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has received a drug registration certificate for Moxifloxacin Hydrochloride Tablets, indicating an expansion in its product portfolio and enhancing its competitive position in the anti-infection market [1][4]. Drug Basic Information - The drug is Moxifloxacin Hydrochloride Tablets, with a specification of 0.4g and classified as a prescription drug [1]. - The drug registration certificate number is 2025S03558, and it is valid for 36 months, expiring on November 24, 2030 [1]. - The drug is approved for various infections, including acute bacterial sinusitis and community-acquired pneumonia [2]. Market and Financial Impact - Moxifloxacin Hydrochloride Tablets have been included in the National Basic Medical Insurance Directory for 2024, with a projected market size of 530 million RMB in China [3]. - The company has invested 13.64 million RMB in the research and development of this drug [3]. - There are currently 24 approved manufacturers for Moxifloxacin Hydrochloride Tablets in China [3]. Company Impact - The approval of Moxifloxacin Hydrochloride Tablets enhances the company's core product offerings in the anti-infection sector, thereby improving its market competitiveness [4]. - The company aims to broaden its business scope and strengthen its product matrix with this new addition [4].